Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 464 across all filing types
Latest filing 2019-05-20 Annual Report
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Annual Report Classification · 95% confidence The document is a detailed statement of audited financial results for the quarter and year ended March 31, 2019, including a balance sheet and notes. It includes the auditor's report with an unmodified opinion, financial data such as income, expenses, profit/loss, and comprehensive income, and is approved by the Board of Directors. The document references compliance with SEBI regulations and Indian Accounting Standards. The length is substantial (15,000 characters), and it contains actual financial statements and analysis, not just an announcement or certification. Therefore, this is a full Annual Report type document covering the company's yearly financial performance. FY 2019
2019-05-20 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding a newspaper advertisement pursuant to a regulatory requirement (Regulation 47 of SEBI Listing Obligations). It is a short communication (1183 characters) that encloses copies of newspaper advertisements and requests the exchanges to take them on record. There is no financial data, no report content, no management discussion, no voting results, no audit information, or any other detailed report. It is essentially a regulatory announcement or compliance communication. According to the rules, such short regulatory announcements that do not contain substantive report content fall under Regulatory Filings (RNS).
2019-05-13 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider and approve audited financial results for the quarter and year ended March 31, 2019. It is an intimation to stock exchanges and public about the upcoming board meeting and trading window closure. The document does not contain the financial results or auditor's report itself, but only announces the meeting where these will be considered. The document length is short (2342 characters) and it is an announcement rather than the report itself. Therefore, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement and meeting intimation, not the actual financial report or audit report.
2019-05-09 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the non-applicability of the SEBI Large Entities framework for fund raising by issuance of debt securities. It references a SEBI circular dated 26th November 2018 and declares that the company is not classified as a Large Corporate under that framework. The document is short (1421 characters), formal, and serves as a regulatory compliance declaration rather than a financial report or detailed announcement. It does not contain financial data, earnings, management discussion, or any report publication. It is not a report itself but a regulatory filing to comply with SEBI requirements. Therefore, it fits best under Regulatory Filings (RNS).
2019-05-02 English
Updates
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March 2019. It is addressed to stock exchanges and signed by the company secretarial officer. The document length is short (2086 characters) and it is a compliance certificate rather than a financial report or detailed filing. It does not contain financial statements or detailed analysis but is a regulatory compliance certificate. According to the rules, such officer certifications or attestations fall under Regulatory Filings (RNS).
2019-05-02 English
Trading Window
Regulatory Filings
2019-04-05 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.